Oral IBAT Inhibitor Improves Cholestatic Itch in Primary Biliary Cholangitis

Oral IBAT Inhibitor Improves Cholestatic Itch in Primary Biliary Cholangitis

(MedPage Today) -- Linerixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, improved cholestatic pruritus in patients with primary biliary cholangitis (PBC), the randomized phase III GLISTEN trial showed. Among 238 patients...

GSK reports results from trial of IBAT inhibitor for itch in PBC patients

GSK has reported positive outcomes from the Phase III GLISTEN trial of linerixibat for cholestatic pruritus (itch) and PBC.The post GSK reports results from trial of IBAT inhibitor for itch in PBC patients appeared first on Clinical Trials Arena.

GSK Reports Results From Trial Of IBAT Inhibitor For Itch In PBC Patients

GSK’s linerixibat works by inhibiting the re-uptake of bile acids. Credit: MAXSHOT.PL / Shutterstock. GSK has reported positive outcomes from the randomised Phase III GLISTEN trial of the targeted inhibitor of ileal bile acid transporter (IBAT), linerixibat. The therapy aims to treat adults with cholestatic pruritus (itch) and primary biliary cholangitis (PBC), an autoimmune liver condition. The trial met its primary endpoint, which was the chan…